MoonLake Immunotherapeutics reported positive Phase 2 data for sonelokimab, an IL‑17 nanobody, in axial spondyloarthritis—achieving an ASAS40 response in 81% of participants at Week 12 and showing imaging and biomarker reductions in joint inflammation. The company said these results kick off a pivotal year of readouts and support confidence ahead of regulatory interactions. MoonLake highlighted PET and MRI evidence of target engagement and biomarker changes that underpin its claim of deep tissue access by the nanobody format. Management expressed confidence as it prepares for an FDA submission pathway and larger trials to confirm clinical durability and safety.